Sanofi's net prices keep slipping—despite list price hikes—thanks to billions in rebates

Created in 2017 in the name of transparency, Sanofi's annual drug pricing report lays out the latest info on the company's price hikes, rebates and rationale for the cost of new medicines. In the report's latest iteration, Sanofi reveals its list prices increased by an average of 1.5% last year but that its average net prices fell by 1.3%.